Physician
Hematology
Dr. William G. Wierda, MD
|
|
Give Review
Doctor William G. Wierda, MD practices Hematology. William Wierda is a published physician as well. He has 102 publications published. The latest was: Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. William Wierda accepts Medicare payments and is listed with Medicare.gov.
Publications
- Outcomes for patients with chronic lymphocytic leukemia and Acute leukemia or myelodysplastic syndrome.
- Analysis of 2013 European LeukaemiaNet (ELN) responses in Chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
- Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia.
- Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
- β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with Chronic lymphocytic...
- Improvement in clinical outcome of FLT3 ITD mutated Acute myeloid leukemia patients over the last one and a half decade.
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive Acute lymphoblastic leukaemia: a single-centre, phase...
- Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic Leukemia.
- Eliminating minimal residual disease as a therapeutic endpoint: working toward cure for patients with CLL.
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic Leukemia.
- Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic Leukemia.
- Outcomes of patients with chronic lymphocytic Leukemia after discontinuing ibrutinib.
- Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.
- Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic Leukemia: final results from a pivotal study.
- High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic Leukemia is an independent predictor of adverse outcome.
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
- Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia.
- Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice.
- Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic Leukemia.
- Regulation of mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic Leukemia.
- Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with Chronic lymphocytic leukae...
- Expression of executioner procaspases and their activation by a procaspase activating compound in chronic lymphocytic Leukemia cells.
- Ibrutinib: a paradigm shift in management of CLL.
- A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic Leukemia.
- Life After FCR: Outcomes of patients with chronic lymphocytic Leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab.
- Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective.
- Safety and activity of ibrutinib plus rituximab for patients with high-risk Chronic lymphocytic leukaemia: a single-arm, phase 2 study.
- FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic Leukemia.
- The use of obinutuzumab in chronic lymphocytic Leukemia.
- Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphoc...
- Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic Leukemia.
- A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia.
- Kinetics of chronic lymphocytic Leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
- STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis.
- Gene Therapy: Charting a Future Course Summary of a National Institutes of Health Workshop, April 12, 2013.
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic Leukemia cells.
- Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic Leukemia.
- Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic Leukemia cells.
- Correlation between FDG/PET findings, histological features, clinical characteristics and survival in 332 patients with chronic lymphocytic Leukemia.
- Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic Leukemia.
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic Lymphoma: an open-label, multicentre, phase 1b/2 trial.
- Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant.
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis.
- The Spiegelmer(R) NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic Leukemia cell motility and causes chemo-sensitization.
- Immunotherapy for chronic lymphocytic Leukemia in the era of BTK inhibitors.
- Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk Myelodysplastic syndrome is associated with poor prognosis and transformation to acut...
- Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic Leukemia: Joint experience of the MD Anders...
- Pneumonia during Remission Induction Chemotherapy in Patients with Acute Leukemia.
- Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic Leukemia: Analysis of persistent and new-onset cytop...
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic Leukemia.
- Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic Leukemia.
- Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic Leukemia.
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Synd...
- Non-Hodgkin's Lymphomas, Version 1.2013.
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
- CARs in Chronic Lymphocytic Leukemia - Ready to Drive.
- Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia: A Comparison of CLL and HapMap Genot...
- Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study.
- Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine.
- Predicting survival of patients with hypoCellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
- Making Advances in First-Line Chronic Lymphocytic Leukemia Treatment.
- Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic Leukemia.
- The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic Leukemia.
- Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic Leukemia B-cell activation and migration.
- Analysis of outcomes in adolescents and young adults with chronic myelogenous Leukemia treated with upfront tyrosine kinase inhibitor therapy.
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease.
- Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic Leukemia cell survival and tissue homing in vitro and in vivo.
- Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic Leukemia.
- Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic Leukemia/small lymphocyti...
- Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia.
- Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic Leukemia.
- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study.
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic Leukemia.
- Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic Leukemia.
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic Leukemia.
- Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic Leukemia.
- Non-Hodgkin's Lymphomas.
- Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic Leukemia.
- LDOC1 mRNA is differentially expressed in chronic lymphocytic Leukemia and predicts overall survival in untreated patients.
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
- What is the best frontline therapy for patients with CLL and 17p deletion?
- CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic Leukemia.
- Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic Leukemia.
- A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia.
- The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic Leukemia.
- Immunohistochemical detection of ZAP70 in chronic lymphocytic Leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.
- Chronic lymphocytic Leukemia: new concepts for future therapy.
- High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic Leukemia.
- Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary Cells.
- Genome-wide DNA methylation profiling of chronic lymphocytic Leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.
- Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic Leukemia and multiple myeloma.
- Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic Leukemia.
- NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's Lymphomas.
- Diverse marrow stromal Cells protect CLL Cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal Cell ad...
- Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic Leukemia cells.
- Long-term outcome of patients with chronic myeloid Leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vit...
- Chronic lymphocytic Leukemia: treatment options for patients with refractory disease.
- De novo deletion 17p13.1 chronic lymphocytic Leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
- Autoimmune cytopenias in patients with chronic lymphocytic Leukemia treated with ibrutinib.
Schools
R Franklin Univ Of Med amp Sci
Duke University Med Center
University Ca San Diego Med Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of California San Diego -
Duke University Hospital -
Rosalind Franklin University of Medicine and Science
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1497848279 | |
| NPPES Provider LastName | WIERDA | |
| NPPES Provider FirstName | WILLIAM | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 517.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 2.13 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497848279 |
| Last Name Of The Provider | WIERDA |
| First Name Of The Provider | WILLIAM |
| View All |
Similar Doctors
|
|
Dr. John M. Carwile, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eugene M. McKelvey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Logothetis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sapna Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Renato Lenzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan K. Kee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Andreeff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Georgios Pongas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Gloria Anyadike, FNP |
|
|
Dr. Nora U. Torres, MD
This Doctor is OpenDoctor Recommended.
|